Crossject
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6 Rue Pauline Kergomard, Dijon, Bourgogn...Phone Number
+33 380549850Website
www.crossject.comRevenue
-Stock Symbol
ALCJIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis.Explore more
Crossject Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Crossject your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Crossject
Funding: Get notified immidiatlly once Crossject has new funding data
Crossject, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Crossject has recently received funding, and reach out quickly before it becomes old news!
Check out if Crossject is spiking on competitors!
Earning: See what the market has to say on Crossject recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Crossject launches new products
Click to see if Crossject had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Crossject is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Crossject is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Crossject.
Crossject financials insights
Gather financial insights about Crossject, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$12M
2024
Unspecified
$7.6M
2025
Multiple Rounds
$23.5M
2026
Stock/Share Issuance
$17.3M
Crossject Tech Stack
A closer look at the technologies used by Crossject
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Person-Based
Funding
Funding
Person-Based
Crossject News & Media
CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory
DIJON, France – 25 March 2026 (07:20 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, currently in the advanced stages of development and registration of ZEPIZURE®, an injectable for the management of epileptic seizures, today publishes its financial results for the financial year ended 31 December 2025.CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Crossject
Sign Up For FreeTo access detailed company insights
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaph... Read More
